Dabigatran vs Durvalumab

Dabigatran vs Durvalumab: Overview

This comparison examines the pharmacological differences between Dabigatran and Durvalumab.

Mechanism of Action

Dabigatran: Direct thrombin (Factor IIa) inhibitor.

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Dabigatran — 12-17 hours; Durvalumab — 17 days.

Chemical Properties

Molecular Formula: Dabigatran — C25H25N7O3.

Molecular Weight: Dabigatran — 471.5100 g/mol.

Type: Dabigatran — Small molecule; Durvalumab — Antibody.